quinazolines has been researched along with olaparib in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 20 (68.97) | 24.3611 |
| 2020's | 9 (31.03) | 2.80 |
| Authors | Studies |
|---|---|
| Aten, JA; Buist, MR; Eppink, B; Essers, J; Franken, NA; Kanaar, R; Krawczyk, PM; O'Connor, MJ; Odijk, H; Rens, J; Rodermond, H; Soullié, T; Stalpers, LJ; Stap, J; Ten Hagen, TL; van Bree, C; Verhagen, HJ; Zelensky, A | 1 |
| Kachnic, LA; Powell, SN | 1 |
| Baird, RD; Barton, DP; Kaye, SB; Khan, AZ; Moreno, V; Vitfell-Pedersen, J; Yap, TA | 1 |
| Birrer, M; Buss, MK; Dahlberg, SE; Fleming, GF; Ivy, P; Lee, H; Liu, JF; Matulonis, UA; Tolaney, SM; Tyburski, K; Whalen, C; Winer, E | 1 |
| Chiou, TT; Gallacchi, D; Kwiatkowski, DJ; Lee, PS; Li, C; Malinowska, IA; Pereira, AM; Reynolds, SB; Robinson, L; Sun, Y; Yu, JJ; Zhang, EY | 1 |
| Barry, WT; Birrer, M; Buckanovich, RJ; Buss, MK; Fleming, GF; Hurteau, J; Ivy, SP; Kohn, EC; Lee, H; Lee, JM; Liu, JF; Luo, W; Matulonis, UA; Nattam, S; Obermayer, L; Quy, P; Rimel, B; Whalen, C; Winer, EP | 1 |
| Battaile, KP; Beletskaya, I; Chirgadze, NY; Gebremeskel, S; Gordon, R; Lam, R; Pai, EF; Qiu, W; Romanov, V; Rottapel, R; Thompson, C; Vodsedalek, J; Voytyuk, O | 1 |
| Schmidt, C | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Cupo, M; Mauritz, M; Mitulovic, G; Węsierska-Gądek, J | 1 |
| Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R | 1 |
| Ivy, SP; Kohn, EC; Lee, JM; Liu, JF; Matulonis, UA | 1 |
| Annunziata, CM; Botesteanu, DA; Cao, L; Cimino-Mathews, A; Figg, WD; Harrell, MI; Ho, TW; Houston, N; Kohn, EC; Lee, JM; Lipkowitz, S; Nguyen, J; Ogurtsova, A; Peer, CJ; Swisher, EM; Taube, JM; Thompson, E; Xu, H; Zimmer, A | 1 |
| Gunn, AR; Kolb, AL; Lakin, ND | 1 |
| Giri, S; Huang, PH; Korayem, Y; Lin, ZP; Lo, YC; LoRusso, P; Moscarelli, J; Ratner, ES; Xiong, A; Zhu, YL | 1 |
| Barry, WT; Birrer, M; Buckanovich, RJ; Buss, MK; Curtis, J; Fleming, GF; Hurteau, J; Ivy, SP; Kohn, EC; Lee, JM; Liu, JF; Luo, W; Matulonis, UA; Nattam, SR; Rimel, BJ; Whalen, C | 1 |
| Gonzalez-Martin, A; Lorusso, D; Pignata, S | 1 |
| Annunziata, CM; Cao, L; Cimino-Mathews, A; Figg, WD; Gatti-Mays, M; Houston, ND; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Mikkilineni, L; Nichols, E; Peer, C; Sharma, R; Trepel, JB; Zimmer, AS | 1 |
| Arrieta, O; Bosch-Barrera, J; Caro, RB; Dómine, M; Drozdowskyj, A; Garcia-Campelo, R; Granados, ALO; Guirado, M; Insa, A; Karachaliou, N; Lianes, P; Majem, M; Massuti, B; Molina-Vila, MA; Reguart, N; Rodriguez-Abreu, D; Rosell, R; Sala, MÁ; Vázquez-Estevez, S; Verdú, A; Vicente, D | 1 |
| Arthur-Darkwa, E; Burnett, E; Counsell, N; El-Khouly, F; Elyashiv, O; Farrelly, L; Feeney, A; Gourley, C; Jayson, GC; Ledermann, J; Macdonald, I; Mileshkin, L; Neto, A; Nicum, S; Parmar, G | 1 |
| Lian, X; Liao, M; Quan, J; Wang, G; Wu, Y; Xie, W; Yang, ZZ; Zhang, Z | 1 |
| Collins, L; Dobbie, S; Dunn, R; Holmes, J; Mansouri, A; McGregor, N; Nicum, S | 1 |
| Cardin, DB; Glazer, PM; Grossman, SR; Ivy, SP; Kato, S; Kim, JW; LoRusso, PM; Shyr, Y; Vaishampayan, UN | 1 |
| Anastasia, A; Arnold, S; Bani, MR; Barry, ST; Bizzaro, F; Cavallaro, U; Damia, G; Fuso Nerini, I; Galbiati, A; Ghilardi, C; Giavazzi, R; Guana, F; Guffanti, F; Hattersley, MM; Leo, E; Minoli, L; Ostano, P; Ramos-Montoya, A; Russo, M; Taylor, MA; Urosevic, J; Williamson, SC | 1 |
| Chhabra, A; Eisen, T; Fife, K; Gallagher, FA; Matakidou, A; Mitchell, TJ; Mossop, H; Oades, G; Ortuzar, MC; Protheroe, A; Sala, E; Sipple, JAN; Skells, R; Stewart, GD; Stone, J; Sullivan, M; Thomas, MG; Ursprung, S; Venugopal, B; Walker, A; Warren, AY; Wason, J; Welsh, SJ; Young, G | 1 |
| Alvisi, MF; Benedetti Panici, P; Biagioli, E; Bologna, A; Carlucci, L; Colombo, N; DeCensi, A; Fossati, R; Lapresa, M; Lissoni, AA; Mancari, R; Nicoletto, MO; Palaia, I; Poli, D; Rulli, E; Tasca, G; Tettamanzi, F; Tognon, G; Tomao, F; Torri, V | 1 |
| Brown, J; Chapman, J; Diaz, JP; Dymond, M; Ghamande, S; Kendrick, J; Kumar, S; Lee, JM; Liu, JF; Lowe, ES; Milenkova, T; Moore, RG; Park, MS; Slomovitz, BM; Tewari, KS | 1 |
3 review(s) available for quinazolines and olaparib
| Article | Year |
|---|---|
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Antiangiogenic therapy in oncology: current status and future directions.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2016 |
10 trial(s) available for quinazolines and olaparib
| Article | Year |
|---|---|
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capsules; Carcinoma, Ovarian Epithelial; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Receptors, Vascular Endothelial Growth Factor; Tablets; Treatment Outcome | 2013 |
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2014 |
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escala
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Hypertension; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum Compounds; Progression-Free Survival; Quinazolines; Response Evaluation Criteria in Solid Tumors; Time Factors | 2019 |
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Goals; Humans; Lung Neoplasms; Mexico; Mutation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spain | 2020 |
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherap
Topics: Adult; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2021 |
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.
Topics: Clinical Trials, Phase II as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biopsy; Capillary Permeability; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Magnetic Resonance Imaging; Medical Futility; Nephrectomy; Non-Randomized Controlled Trials as Topic; Phthalazines; Piperazines; Proof of Concept Study; Quinazolines; Treatment Outcome; Tumor Burden | 2021 |
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Phthalazines; Piperazines; Quinazolines | 2022 |
16 other study(ies) available for quinazolines and olaparib
| Article | Year |
|---|---|
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.
Topics: Animals; Benzoquinones; BRCA2 Protein; Cell Line; Cell Line, Tumor; Cells, Cultured; DNA Repair; DNA-Binding Proteins; Embryonic Stem Cells; Female; HeLa Cells; Hot Temperature; Humans; Immunoblotting; Lactams, Macrocyclic; Mice; Mice, Nude; Neoplasms, Experimental; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Recombination, Genetic; RNA Interference; Transplantation, Heterologous; Tumor Burden | 2011 |
Homologous recombination research is heating up and ready for therapy.
Topics: Animals; Benzoquinones; BRCA2 Protein; Cell Line, Tumor; DNA Repair; DNA-Binding Proteins; Hot Temperature; Humans; Immunoblotting; Lactams, Macrocyclic; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Recombination, Genetic; RNA Interference; Transplantation, Heterologous; Tumor Burden | 2011 |
The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.
Topics: Adenocarcinoma, Papillary; Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Phthalazines; Piperazines; Quinazolines; Uterine Cervical Neoplasms | 2012 |
Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Topics: Animals; Antineoplastic Agents; Cell Line; DNA Repair; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Humans; Isoquinolines; Lung Neoplasms; Lymphangioleiomyomatosis; Mice, Inbred C57BL; Mice, SCID; Molecular Targeted Therapy; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Sirolimus; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Drug combo may be effective in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines | 2014 |
Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
Topics: Benzamides; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Catalytic Domain; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Models, Molecular; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Conformation; Pyrimidinones; Quinazolines; Tankyrases | 2014 |
Cediranib aims for a comeback.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Female; Humans; Myelodysplastic Syndromes; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Protein-Tyrosine Kinases; Quinazolines; United Kingdom; United States; Uterine Cervical Neoplasms; Vaginal Fistula; Vascular Endothelial Growth Factor A; Weight Loss | 2015 |
Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Topics: Apoptosis; Benzamides; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines | 2015 |
Redundancy between nucleases required for homologous recombination promotes PARP inhibitor resistance in the eukaryotic model organism Dictyostelium.
Topics: ADP Ribose Transferases; Benzamides; Clone Cells; Cyclin-Dependent Kinase 8; Dictyostelium; DNA Damage; Drug Resistance; Exodeoxyribonucleases; Gene Deletion; Homologous Recombination; Indoles; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protozoan Proteins; Quinazolines; Rad51 Recombinase; Recombinant Proteins | 2017 |
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice, Nude; Mice, SCID; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyridines; Quinazolines; Thiosemicarbazones; Xenograft Model Antitumor Assays | 2018 |
Chemotherapy-free treatments: are we ready for prime time?
Topics: Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Progression-Free Survival; Quinazolines; Time | 2019 |
Mechanism of Cediranib-Olaparib Combo Revealed.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Down-Regulation; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Rad51 Recombinase | 2019 |
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
Topics: Animals; Autophagosomes; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice, Nude; Microtubule-Associated Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Protein Kinase Inhibitors; Quinazolines; Sequestosome-1 Protein; Signal Transduction | 2020 |
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
Topics: Adenocarcinoma; Female; Humans; Mutation; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mice, Nude; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Signal Transduction; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2021 |
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Topics: Adolescent; Adult; Bevacizumab; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Indoles; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines | 2022 |